These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
292 related articles for article (PubMed ID: 26415776)
1. Enhanced efficacy of chemotherapy for breast cancer stem cells by simultaneous suppression of multidrug resistance and antiapoptotic cellular defense. Sun M; Yang C; Zheng J; Wang M; Chen M; Le DQS; Kjems J; Bünger CE Acta Biomater; 2015 Dec; 28():171-182. PubMed ID: 26415776 [TBL] [Abstract][Full Text] [Related]
2. Adenovirus adenine nucleotide translocator-2 shRNA effectively induces apoptosis and enhances chemosensitivity by the down-regulation of ABCG2 in breast cancer stem-like cells. Jang JY; Kim MK; Jeon YK; Joung YK; Park KD; Kim CW Exp Mol Med; 2012 Apr; 44(4):251-9. PubMed ID: 22198296 [TBL] [Abstract][Full Text] [Related]
3. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model. Tiash S; Chowdhury EH J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549 [TBL] [Abstract][Full Text] [Related]
4. Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Kim TH; Shin YJ; Won AJ; Lee BM; Choi WS; Jung JH; Chung HY; Kim HS Biochim Biophys Acta; 2014 Jan; 1840(1):615-25. PubMed ID: 24161697 [TBL] [Abstract][Full Text] [Related]
5. Standard chemotherapy impacts on in vitro cellular heterogeneity in spheroids enriched with cancer stem cells (CSCs) derived from triple-negative breast cancer cell line. Moreira MP; Franco EP; Barros BAF; Anjos BRD; Almada DG; Barbosa INT; Braga LDC; Cassali GD; Silva LM Biochem Biophys Res Commun; 2024 Nov; 734():150765. PubMed ID: 39357337 [TBL] [Abstract][Full Text] [Related]
6. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694 [TBL] [Abstract][Full Text] [Related]
7. Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells. Chen L; Luo J; Zhang J; Wang S; Sun Y; Liu Q; Cheng C Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511335 [TBL] [Abstract][Full Text] [Related]
8. Quinacrine and curcumin synergistically increased the breast cancer stem cells death by inhibiting ABCG2 and modulating DNA damage repair pathway. Nayak D; Tripathi N; Kathuria D; Siddharth S; Nayak A; Bharatam PV; Kundu C Int J Biochem Cell Biol; 2020 Feb; 119():105682. PubMed ID: 31877386 [TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase (HDAC) inhibitors and doxorubicin combinations target both breast cancer stem cells and non-stem breast cancer cells simultaneously. Hii LW; Chung FF; Soo JS; Tan BS; Mai CW; Leong CO Breast Cancer Res Treat; 2020 Feb; 179(3):615-629. PubMed ID: 31784862 [TBL] [Abstract][Full Text] [Related]
10. Continuous exposure to doxorubicin induces stem cell-like characteristics and plasticity in MDA-MB-231 breast cancer cells identified with the SORE6 reporter. Salinas-Jazmín N; Medina-Mondragón MA; Jiménez-López J; Guerrero-Rodríguez SL; Cuautle-Rodríguez P; Velasco-Velázquez MA Cancer Chemother Pharmacol; 2024 Oct; 94(4):571-583. PubMed ID: 39180549 [TBL] [Abstract][Full Text] [Related]
11. Effect of β-elemene on the kinetics of intracellular transport of d-luciferin potassium salt (ABC substrate) in doxorubicin-resistant breast cancer cells and the associated molecular mechanism. Tang CY; Zhu LX; Yu JD; Chen Z; Gu MC; Mu CF; Liu Q; Xiong Y Eur J Pharm Sci; 2018 Jul; 120():20-29. PubMed ID: 29704644 [TBL] [Abstract][Full Text] [Related]
12. Caveolin-1 mediates chemoresistance in breast cancer stem cells via β-catenin/ABCG2 signaling pathway. Wang Z; Wang N; Li W; Liu P; Chen Q; Situ H; Zhong S; Guo L; Lin Y; Shen J; Chen J Carcinogenesis; 2014 Oct; 35(10):2346-56. PubMed ID: 25085904 [TBL] [Abstract][Full Text] [Related]
13. IMD-0354 targets breast cancer stem cells: a novel approach for an adjuvant to chemotherapy to prevent multidrug resistance in a murine model. Gomez-Cabrero A; Wrasidlo W; Reisfeld RA PLoS One; 2013; 8(8):e73607. PubMed ID: 24014113 [TBL] [Abstract][Full Text] [Related]
14. Novel dendritic polyglycerol-conjugated, mesoporous silica-based targeting nanocarriers for co-delivery of doxorubicin and tariquidar to overcome multidrug resistance in breast cancer stem cells. Pan Y; Zhou S; Li Y; Parshad B; Li W; Haag R J Control Release; 2021 Feb; 330():1106-1117. PubMed ID: 33189788 [TBL] [Abstract][Full Text] [Related]
15. Simultaneous modulation of multidrug resistance and antiapoptotic cellular defense by MDR1 and BCL-2 targeted antisense oligonucleotides enhances the anticancer efficacy of doxorubicin. Pakunlu RI; Cook TJ; Minko T Pharm Res; 2003 Mar; 20(3):351-9. PubMed ID: 12669953 [TBL] [Abstract][Full Text] [Related]
16. Co-Eradication of Breast Cancer Cells and Cancer Stem Cells by Cross-Linked Multilamellar Liposomes Enhances Tumor Treatment. Kim YJ; Liu Y; Li S; Rohrs J; Zhang R; Zhang X; Wang P Mol Pharm; 2015 Aug; 12(8):2811-22. PubMed ID: 26098197 [TBL] [Abstract][Full Text] [Related]
17. Reversing multidrug resistance in breast cancer cells by silencing ABC transporter genes with nanoparticle-facilitated delivery of target siRNAs. Li YT; Chua MJ; Kunnath AP; Chowdhury EH Int J Nanomedicine; 2012; 7():2473-81. PubMed ID: 22701315 [TBL] [Abstract][Full Text] [Related]
18. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066. Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424 [TBL] [Abstract][Full Text] [Related]
19. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression. Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760 [TBL] [Abstract][Full Text] [Related]
20. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells. Abdin SM; Tolba MF; Zaher DM; Omar HA Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]